8-K: Femasys Reports 2025 Results, Advances FemBloc & FemaSeed

Femasys Inc. announced its financial results for the year ended December 31, 2025, reporting increased sales and significant progress in its FemBloc and FemaSeed product lines.

Summary

• Sales increased by $664,205, or 40.8%, to $2,293,313 in 2025 from $1,629,108 in 2024, primarily due to sales of FemBloc.
• Net loss was $18,627,887, or ($0.47) per basic and diluted share attributable to common stockholders, for the year ended December 31, 2025, compared to a net loss of $18,816,628, or ($0.85) per share, for 2024.
• Cash and cash equivalents as of December 31, 2025, were approximately $9.3 million, with an accumulated deficit of approximately $145.8 million.
• The company expects its current cash and cash equivalents to be sufficient to fund ongoing operations into the third quarter of 2026.
• Patient enrollment was initiated in the FDA-authorized FINALE pivotal clinical trial for FemBloc, advancing toward U.S. approval.
• FemBloc achieved certification under the Medical Device Single Audit Program (MDSAP) and received full regulatory approval in Europe (June 2025), the UK (August 2025), and New Zealand (September 2025).
• Received AMA CPT Editorial Panel approval of a new Category III CPT code for FemaSeed intratubal insemination (ITI), supporting future reimbursement.
• Secured FDA 510(k) clearance for the FemVue Controlled device, an innovative solution for evaluating fallopian tube status.
• Completed a $12 million financing, strengthening the balance sheet to support ongoing clinical and commercial execution.
• Appointed Kenneth D. Eichenbaum, M.D., M.S.E., to the Board of Directors, strengthening leadership and strategic oversight.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update, reflecting strong operational progress and sales growth, though tempered by ongoing net losses and a limited cash runway requiring future financing.

Positives

• Sales increased by $664,205, or 40.8%, to $2,293,313 in 2025, primarily driven by FemBloc sales.
• Net loss per basic and diluted share improved to ($0.47) in 2025 from ($0.85) in 2024.
• Research and development expenses decreased by $638,839, or 7.8%, to $7,577,704 in 2025.
• Initiated patient enrollment in the FINALE pivotal clinical trial for FemBloc, a key step toward U.S. FDA approval.
• FemBloc achieved Medical Device Single Audit Program (MDSAP) certification, supporting global regulatory readiness.
• FemBloc received full regulatory approval in Europe (June 2025), the UK (August 2025), and New Zealand (September 2025).
• Received AMA CPT Editorial Panel approval of a new Category III CPT code for FemaSeed, supporting future reimbursement pathways.
• Secured FDA 510(k) clearance for the FemVue Controlled device.
• Completed a $12 million financing, strengthening the balance sheet.
• Appointed Kenneth D. Eichenbaum, M.D., M.S.E., to the Board of Directors, enhancing leadership and strategic oversight.
• Entered a strategic distribution partnership with OR Consulting for commercial launch in Switzerland.
• Established a partnership with Refuah Health Center, advancing adoption of FemaSeed in community-based care.

Negatives

• Reported a net loss of $18,627,887 for the year ended December 31, 2025.
• Accumulated deficit of approximately $145.8 million as of December 31, 2025.
• Current cash and cash equivalents of approximately $9.3 million are only sufficient to fund operations into the third quarter of 2026, indicating a need for future financing.
• Interest expense increased to $1,891,119 in 2025 from $1,603,575 in 2024.

Risks

• Ability to obtain regulatory approvals for the FemBloc product candidate.
• Ability to develop and advance the current FemBloc product candidate and successfully enroll and complete the clinical trial.
• The ability of clinical trials to demonstrate safety and effectiveness of product candidates and other positive results.
• Estimates regarding the total addressable market for products and product candidates.
• Ability to commercialize products and product candidates.
• Ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing products, including FemaSeed.
• Business model and strategic plans for products, technologies, and business, including implementation thereof.
• Other risks and uncertainties described in the section titled Risk Factors in the Annual Report on Form 10-K for the year ended December 31, 2025, when filed.

Future Outlook

Femasys expects its current cash and cash equivalents to be sufficient to fund ongoing operations into the third quarter of 2026. The company is actively advancing FemBloc with the FINALE pivotal clinical trial for U.S. FDA approval and expanding FemaSeed commercialization in the U.S. with the introduction of the FemSperm product family.

Management Comments

• "During the fourth quarter of 2025 and into the first quarter of 2026 we achieved significant clinical, regulatory and commercial milestones for our FemBloc non-surgical permanent birth control and our FemaSeed first-line intratubal insemination product solutions."
• "We are actively expanding FemaSeed commercialization in the U.S. with the introduction of the FemSperm product family, which enables gynecologists to perform in-office sperm preparation and analysis for use with our first-step infertility treatment."
• "Concurrently, we are advancing FemBloc with the initiation of patient enrollment in the FINALE pivotal clinical trial, a key step toward U.S. FDA approval."
• "We believe we have sufficient cash to fund operations into the third quarter of 2026."
• "We continue to strive to redefine women's reproductive health by addressing critical gaps with innovative, safe, and technologically advanced solutions."

Industry Context

StockSavvy.ai notes that Femasys's focus on non-surgical permanent birth control and first-line infertility treatments addresses significant unmet needs in women's reproductive health. The regulatory approvals for FemBloc in Europe, the UK, and New Zealand, alongside the initiation of the FINALE pivotal trial for U.S. FDA approval, position Femasys to potentially disrupt established markets dominated by surgical procedures and more invasive fertility treatments. The approval of a new CPT code for FemaSeed is crucial for market adoption and reimbursement, aligning with broader industry trends towards less invasive, in-office procedures.

Comparison to Industry Standards

• FemaSeed achieved more than double the pregnancy rate of traditional IUI, with a comparable safety profile, based on published clinical trial data.
• FemBloc is presented as the first and only non-surgical, in-office alternative to centuries-old surgical sterilization, suggesting a significant competitive advantage if U.S. approval is secured.
• Published data from initial FemBloc clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value through product commercialization and regulatory approvals, but also dilution risk from future capital raises and ongoing losses.
• Patients (Women): Access to more accessible and cost-effective fertility treatments (FemaSeed, FemSperm) and non-surgical permanent birth control (FemBloc).
• Practitioners (Gynecologists): New in-office solutions for sperm preparation/analysis (FemSperm), fallopian tube assessment (FemVue), and non-surgical permanent contraception (FemBloc).
• Employees: Continued employment and potential growth opportunities as products advance.
• Creditors: Risk associated with ongoing net losses and accumulated deficit, though mitigated by recent financing.

Next Steps

• Continue patient enrollment in the FINALE pivotal clinical trial for FemBloc toward U.S. FDA approval.
• Expand FemaSeed commercialization in the U.S. with the FemSperm product family.
• Continue European post-market surveillance study for FemBloc.
• Commercial launch of FemBloc, FemaSeed, and other products in Switzerland through OR Consulting partnership.
• Advance adoption of FemaSeed as a first-line infertility treatment in community-based care with Refuah Health Center.
• File Annual Report on Form 10-K for the year ended December 31, 2025.

Key Dates

Recommendation

Femasys demonstrates strong operational progress with increased sales, multiple regulatory approvals for FemBloc, and advancements in its FemaSeed and FemVue product lines. The improvement in net loss per share and the recent $12 million financing are positive. However, the company continues to operate at a significant net loss and has a limited cash runway into Q3 2026, indicating a high likelihood of further dilution. While the long-term potential is promising given the innovative products, the immediate financial position warrants a 'hold' as investors await further clarity on the FINALE trial results and future financing plans.

Keywords

Femasys, FEMY, FemBloc, FemaSeed, FemVue, birth control, fertility, medical device, FDA approval, clinical trial, FINALE, women's health, reproductive health, medical technology, CPT code, financing, Nasdaq